+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

S1006 Efficacy and Safety of Peginterferon Alfa-2a or 2b Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Germany: the Practice Study



S1006 Efficacy and Safety of Peginterferon Alfa-2a or 2b Plus Ribavirin in the Routine Daily Treatment of Chronic Hepatitis C Patients in Germany: the Practice Study



Gastroenterology 134(4): A-773




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 067059583

Download citation: RISBibTeXText

DOI: 10.1016/s0016-5085(08)63611-2


Related references

Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: the PRACTICE study. Journal of Viral Hepatitis 17(7): 459-468, 2010

T1993 Comparison of the Efficacy of Peginterferon Alfa-2a and -2B Plus Ribavirin in the Treatment of Chronic Hepatitis C Patients in Daily Routine: Results From Practice. Gastroenterology 138(5): S-844-S-845, 2010

Efficacy and safety of 22 weeks of maintenance therapy with Peginterferon alfa-2a alone versus Peginterferon alfa-2a plus ribavirin in naive patients with chronic hepatitis C and genotype 1 who responded to a 24-week course of Peginterferon alfa-2a plus ribavirin An open, multicenter, randomized Trial. Hepatology 38(4 Suppl 1): 244A-245A, 2003

Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. Journal of Managed Care Pharmacy 11(8): 687-694, 2005

Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin. American Journal of Health-System Pharmacy 66(24): 2171-2178, 2009

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia. Srpski Arhiv Za Celokupno Lekarstvo 140(7-8): 448-455, 2012

Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection. Medicinski Pregled 59(9-10): 415-419, 2007

Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study. Gut and Liver 6(1): 98, 2012

Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C. Zhonghua Gan Zang Bing Za Zhi 21(7): 506-509, 2013

Treatment and outcome of genotype 4 chronic hepatitis C patients with peginterferon alfa 2b and ribavirin in the clinical setting in Germany. 2007

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus. Korean Journal of Hepatology 17(3): 199-205, 2011

Treatment of chronic hepatitis c with peginterferon alfa-2A (400) (PEG) and ribavirin (RBV) in naive patients with HIV-HCV co-infection in the real-life setting in germany. 2007

Comparison of efficacy of treatment with peginterferon alfa-2a plus ribavirin vs peginterferon alfa-2b plus ribavirin among patients chronically infected with non 2/3 HCV genotypes with low and high pretreatment viral load. 2007

Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Digestion 78(2-3): 123-130, 2008

Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection. Gastroenterologie Clinique et Biologique 31(6-7): 566-572, 2007